Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van Sells 3,553 Shares

Laboratory Co. of America Holdings (NYSE:LHGet Free Report) EVP Der Vaart Sandra D. Van sold 3,553 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $216.74, for a total value of $770,077.22. Following the completion of the sale, the executive vice president now directly owns 7,637 shares of the company’s stock, valued at approximately $1,655,243.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Laboratory Co. of America Stock Performance

NYSE:LH opened at $218.46 on Friday. The company’s 50-day moving average is $218.91 and its two-hundred day moving average is $214.11. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.17 and a quick ratio of 1.02. The firm has a market capitalization of $18.37 billion, a price-to-earnings ratio of 46.78, a PEG ratio of 1.65 and a beta of 1.02. Laboratory Co. of America Holdings has a 1-year low of $174.20 and a 1-year high of $234.09.

Laboratory Co. of America (NYSE:LHGet Free Report) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.29 by $0.01. Laboratory Co. of America had a return on equity of 13.99% and a net margin of 3.24%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.02 billion. During the same period last year, the company earned $4.14 EPS. The company’s quarterly revenue was down 17.5% on a year-over-year basis. Analysts forecast that Laboratory Co. of America Holdings will post 14.77 EPS for the current year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 13th. Shareholders of record on Tuesday, February 27th were given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date was Monday, February 26th. Laboratory Co. of America’s payout ratio is 61.67%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Provence Wealth Management Group acquired a new stake in Laboratory Co. of America during the 3rd quarter worth approximately $29,000. Mendota Financial Group LLC purchased a new position in Laboratory Co. of America in the fourth quarter valued at $29,000. Eagle Bay Advisors LLC purchased a new stake in Laboratory Co. of America during the 2nd quarter worth about $29,000. Tradewinds Capital Management LLC purchased a new position in shares of Laboratory Co. of America in the 3rd quarter valued at about $34,000. Finally, Exchange Traded Concepts LLC purchased a new stake in shares of Laboratory Co. of America during the third quarter worth approximately $37,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on LH shares. Evercore ISI assumed coverage on shares of Laboratory Co. of America in a research note on Friday, February 9th. They issued an “in-line” rating and a $240.00 target price for the company. Barclays began coverage on Laboratory Co. of America in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $222.00 target price on the stock. Argus upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research note on Monday, March 25th. TheStreet cut shares of Laboratory Co. of America from a “b-” rating to a “c+” rating in a report on Thursday, February 15th. Finally, SVB Leerink began coverage on Laboratory Co. of America in a report on Monday, February 26th. They issued an “outperform” rating and a $260.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.50.

Check Out Our Latest Report on Laboratory Co. of America

Laboratory Co. of America Company Profile

(Get Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).

Read More

Insider Buying and Selling by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.